Study to Assess the Safety and Immunological Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI (Mel55)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2013 by University of Virginia.
Recruitment status was  Active, not recruiting
Information provided by (Responsible Party):
Craig L Slingluff, Jr, University of Virginia Identifier:
First received: July 19, 2011
Last updated: September 19, 2013
Last verified: September 2013
No Study Results Posted on for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2013
  Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)